Danny Mena - nuclear medicine(@dandanmena) 's Twitter Profile Photo

TheraP trial ProsTIC used PET PSMA + FDG to get a better patient selection for 177Lu-PSMA.

But, match / missmatch can be a challenge in daily practice.

Thks MIM Software !!

✅ left - PSMA / right - FDG
✅ Cyan: match PSMA / FDG
✅ Blue: just PSMA
✅ Red: just FDG

account_circle
Danny Mena - nuclear medicine(@dandanmena) 's Twitter Profile Photo

New frontiers for 177Lu PSMA SPECT together with dosimetry.

✅ TTB 177Lu-PSMA
✅ Cuantitative SPECT with a Siemens Symbia gamma camera with the power of MIM Software SPECTRA mimsoftware.com/nuclear-medici…
✅ Dosimetry (Gy/lesion)

Building our experience Osvaldo Garcia Cecilia Carreras

account_circle
Diagnostics News(@diagnosticsnews) 's Twitter Profile Photo

GE HealthCare firma acuerdo para adquirir empresa líder en Inteligencia Artificial: MIM Software

diagnosticsnews.com/noticias/42235…

account_circle
Danny Mena - nuclear medicine(@dandanmena) 's Twitter Profile Photo

We really enjoy use technology and do our daily practice connected with TheraP trial from ProsTIC Michael Hofman for 177Lu-PSMA patient selection criteria.

What a great team! Cecilia Carreras Velázquez Cecilia Carreras Jorge Schalch

MIM Software Nuclear Medicine World UroTeragLATAM UroTarget

account_circle
GE HealthCare(@GEHealthCare) 's Twitter Profile Photo

We're excited to share the news that we've acquired MIM Software! 🎉 The company's offerings align closely with our GE HealthCare precision care strategy and mission to deliver innovative digital solutions for patients globally.

Learn more about the acquisition here:

We're excited to share the news that we've acquired @mimsoftware! 🎉 The company's offerings align closely with our GE HealthCare precision care strategy and mission to deliver innovative digital solutions for patients globally.

Learn more about the acquisition here:
account_circle
UC San Diego Rad Med(@UCSDRadMed) 's Twitter Profile Photo

Congratulations to our rockstar residents! Drs. Megan Orr (Megan Orr) and Anna Dornisch (@adornisch_MD) won ACRO - American College of Radiation Oncology MIM Software Travel Awards, and Dr. Shelley Tibbs (@shelley_tibbs) is the recipient of the ACRO Luther Brady Award!

Congratulations to our rockstar residents! Drs. Megan Orr (@MeganEOrr) and Anna Dornisch (@adornisch_MD) won @ACRORadOnc @mimsoftware Travel Awards, and Dr. Shelley Tibbs (@shelley_tibbs) is the recipient of the ACRO Luther Brady Award! #RadOnc
account_circle
Nuclear Medicine World(@nmwlatam) 's Twitter Profile Photo

Contar con la tecnología correcta, MIM Software , en nuestro día a día de trabajo regional y de Segunda Opinión, nos permite apoyarnos en las mejores herramientas diagnósticas fusionadas para incrementar la especificidad de cada método y acercarnos eficientemente al diagnóstico.

Contar con la tecnología correcta, @mimsoftware , en nuestro día a día de trabajo regional y de Segunda Opinión, nos permite apoyarnos en las mejores herramientas diagnósticas fusionadas para incrementar la especificidad de cada método y acercarnos eficientemente al diagnóstico.
account_circle
Elekta(@Elekta) 's Twitter Profile Photo

Exciting news! We've collaborated with GE HealthCare's MIM Software to develop advanced vendor-agnostic treatment applications using industry-leading auto-contouring and treatment planning software solutions. Read more ➡️ bit.ly/44e8Gsf

Exciting news! We've collaborated with @GEHealthCare's @mimsoftware to develop advanced vendor-agnostic #radonc treatment applications using industry-leading auto-contouring and treatment planning software solutions. Read more ➡️ bit.ly/44e8Gsf
account_circle
UroTeragLATAM(@UroTeragLATAM) 's Twitter Profile Photo

Resistance to 177Lu-PSMA??

☑️ Multi-factorial
☑️ VISION trial more resistance than TheraP trial: why?
☑️ Tumor low dose: dosimetry?
☑️ Target expression: SUVmax or SUVmean?
☑️ Heterogeneity?

PSMA conference - UCSF/UCLA/PCF/Urotoday Jeremie Calais Michael Hofman ProsTIC MIM Software

Resistance to 177Lu-PSMA??

☑️ Multi-factorial 
☑️ VISION trial more resistance than TheraP trial: why?
☑️ Tumor low dose: dosimetry?
☑️ Target expression: SUVmax or SUVmean? 
☑️ Heterogeneity? 

@PSMAconference @CalaisJeremie @DrMHofman @pros_tic @mimsoftware
account_circle